254 related articles for article (PubMed ID: 27826368)
1. Native and Reconstituted Plasma Lipoproteins in Nanomedicine: Physicochemical Determinants of Nanoparticle Structure, Stability, and Metabolism.
Pownall HJ; Rosales C; Gillard BK; Ferrari M
Methodist Debakey Cardiovasc J; 2016 Sep; 12(3):146-150. PubMed ID: 27826368
[TBL] [Abstract][Full Text] [Related]
2. High-Density Lipoproteins: Nature's Multifunctional Nanoparticles.
Kuai R; Li D; Chen YE; Moon JJ; Schwendeman A
ACS Nano; 2016 Mar; 10(3):3015-41. PubMed ID: 26889958
[TBL] [Abstract][Full Text] [Related]
3. Tanshinone IIA-loaded reconstituted high density lipoproteins: Atherosclerotic plaque targeting mechanism in a foam cell model and pharmacokinetics in rabbits.
Zhang W; Li J; Liu J; Wu Z; Xu Y; Wang J
Pharmazie; 2012 Apr; 67(4):324-30. PubMed ID: 22570939
[TBL] [Abstract][Full Text] [Related]
4. Lipoprotein Like Nanoparticles Used in Drug and Gene Delivery.
Varshosaz J; Vakilzadeh H; Ghassami E
Curr Pharm Des; 2016; 22(22):3466-85. PubMed ID: 26861646
[TBL] [Abstract][Full Text] [Related]
5. Artificial High Density Lipoprotein Nanoparticles in Cardiovascular Research.
Kornmueller K; Vidakovic I; Prassl R
Molecules; 2019 Aug; 24(15):. PubMed ID: 31382521
[TBL] [Abstract][Full Text] [Related]
6. Liposome-nanoparticle hybrids for multimodal diagnostic and therapeutic applications.
Al-Jamal WT; Kostarelos K
Nanomedicine (Lond); 2007 Feb; 2(1):85-98. PubMed ID: 17716195
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of reconstituted high-density lipoprotein (rHDL) as a drug delivery platform - a detailed survey of rHDL particles ranging from biophysical properties to clinical implications.
Simonsen JB
Nanomedicine; 2016 Oct; 12(7):2161-2179. PubMed ID: 27237620
[TBL] [Abstract][Full Text] [Related]
8. A high-density lipoprotein-mediated drug delivery system.
Mo ZC; Ren K; Liu X; Tang ZL; Yi GH
Adv Drug Deliv Rev; 2016 Nov; 106(Pt A):132-147. PubMed ID: 27208399
[TBL] [Abstract][Full Text] [Related]
9. Nanotechnology and glaucoma: a review of the potential implications of glaucoma nanomedicine.
Kim NJ; Harris A; Gerber A; Tobe LA; Amireskandari A; Huck A; Siesky B
Br J Ophthalmol; 2014 Apr; 98(4):427-31. PubMed ID: 24246373
[TBL] [Abstract][Full Text] [Related]
10. Liposomal drug delivery systems: from concept to clinical applications.
Allen TM; Cullis PR
Adv Drug Deliv Rev; 2013 Jan; 65(1):36-48. PubMed ID: 23036225
[TBL] [Abstract][Full Text] [Related]
11. Lipid transfer protein transports compounds from lipid nanoparticles to plasma lipoproteins.
Seki J; Sonoke S; Saheki A; Koike T; Fukui H; Doi M; Mayumi T
Int J Pharm; 2004 May; 275(1-2):239-48. PubMed ID: 15081154
[TBL] [Abstract][Full Text] [Related]
12. Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine.
Al-Jamal WT; Kostarelos K
Acc Chem Res; 2011 Oct; 44(10):1094-104. PubMed ID: 21812415
[TBL] [Abstract][Full Text] [Related]
13. Physico-chemical and physiological determinants of lipo-nanoparticle stability.
Pownall HJ; Liu J; Gillard BK; Yelamanchili D; Rosales C
Nanomedicine; 2021 Apr; 33():102361. PubMed ID: 33540069
[TBL] [Abstract][Full Text] [Related]
14. Radiolabeled liposomes and lipoproteins as lipidic nanoparticles for imaging and therapy.
Aranda-Lara L; Morales-Avila E; Luna-Gutiérrez MA; Olivé-Alvarez E; Isaac-Olivé K
Chem Phys Lipids; 2020 Aug; 230():104934. PubMed ID: 32562666
[TBL] [Abstract][Full Text] [Related]
15. Lipid Nanoparticles and their Application in Nanomedicine.
Rajabi M; Mousa SA
Curr Pharm Biotechnol; 2016; 17(8):662-72. PubMed ID: 27087491
[TBL] [Abstract][Full Text] [Related]
16. Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems.
Kraft JC; Freeling JP; Wang Z; Ho RJ
J Pharm Sci; 2014 Jan; 103(1):29-52. PubMed ID: 24338748
[TBL] [Abstract][Full Text] [Related]
17. Nanomedicine strategies for drug delivery to the ear.
Pritz CO; Dudás J; Rask-Andersen H; Schrott-Fischer A; Glueckert R
Nanomedicine (Lond); 2013 Jul; 8(7):1155-72. PubMed ID: 23837855
[TBL] [Abstract][Full Text] [Related]
18. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W
Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697
[TBL] [Abstract][Full Text] [Related]
19. Lipoproteins for therapeutic delivery: recent advances and future opportunities.
Raut S; Dasseux JL; Sabnis NA; Mooberry L; Lacko A
Ther Deliv; 2018 Mar; 9(4):257-268. PubMed ID: 29495929
[TBL] [Abstract][Full Text] [Related]
20. Surface-active liposomes for targeted cancer therapy.
Sofou S
Nanomedicine (Lond); 2007 Oct; 2(5):711-24. PubMed ID: 17976032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
